Dr. Jacques Van Dam, MD, PhD

Dr. Van Dam practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Van Dam's NPI, 1518001791, was assigned on February 19, 2007. Dr. Van Dam graduated from Georgetown University School Of Medicine in 1984. Dr. Van Dam holds California license 50435.

Dr. Van Dam's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (626) 256-4673.

Dr. Van Dam's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. Dr. Van Dam is also affiliated with Keck Hospital of USC. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Van Dam to 1 more hospital, 2 group practices and clinics, 1 other site and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Van Dam practices, 5 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Van Dam's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Van Dam is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Van Dam's licenses on file in 3 states: California, Ohio and Massachusetts.

Dmand AI lists acid reflux, colonoscopy, gastroduodenitis, gastroenteritis, gastrointestinal bleeding, pancreas or bile duct endoscopy (ERCP) and upper GI endoscopy among the conditions Dr. Van Dam treats.

CMS data shows 136 Medicare services from Dr. Van Dam across 7 procedure codes in 2024, for 127 Medicare patients. Medicare paid $15,613 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 127 Medicare patients who saw Dr. Van Dam in 2024. The largest group is 65 to 74, with 64 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 43% are also on Medicaid. Their average risk score is 2.28, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Van Dam's median patient age at 70, with 46% women.

In 2024, Dr. Van Dam wrote 33 Medicare Part D claims for 20 patients. 97% of them were for generic drugs. CMS names the drug for 17 of them, across 1 drug with 11 or more claims each, at $43 in total drug cost. In 2023, CMS named 21 claims across 1 drug.

Dr. Van Dam accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 41 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Van Dam, more than 60% of the clinicians it reports for that procedure.

Dmand AI links 14 papers to Dr. Van Dam, published from 2011 to 2025. 2014 was the busiest year, with 2. The most frequent topics are Breast Neoplasms. Dr. Van Dam's most frequent co-authors are James Leonard Buxbaum, MD, Shai Friedland, MD and Ara B. Sahakian, MD.

Dmand AI links Dr. Van Dam to 4 clinical trials, 2 of them phase 2 studies. Conditions studied include Breast Neoplasms, Gastrointestinal Stromal Tumors and Pancreatic Cyst. NanOlogy, LLC sponsors the most, 2.

CMS Open Payments shows 13 general payments to Dr. Van Dam from 2 drug and device companies from 2016 to 2019. Consulting fees make up the largest share, 42% of the total. Boston Scientific Corporation paid the most, $25,120.

Dr. Van Dam graduated from Georgetown University School Of Medicine in 1984.

Dr. Van Dam is in network with 7 carriers, including Elevance, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.